GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rani Therapeutics Holdings Inc (NAS:RANI) » Definitions » EV-to-Revenue

RANI (Rani Therapeutics Holdings) EV-to-Revenue : (As of Dec. 13, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Rani Therapeutics Holdings EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Rani Therapeutics Holdings's enterprise value is $61.29 Mil. Rani Therapeutics Holdings's Revenue for the trailing twelve months (TTM) ended in Sep. 2024 was $0.00 Mil. Therefore, Rani Therapeutics Holdings's EV-to-Revenue for today is .

The historical rank and industry rank for Rani Therapeutics Holdings's EV-to-Revenue or its related term are showing as below:

During the past 5 years, the highest EV-to-Revenue of Rani Therapeutics Holdings was 209.30. The lowest was -6.21. And the median was 37.03.

RANI's EV-to-Revenue is not ranked *
in the Biotechnology industry.
Industry Median: 7.65
* Ranked among companies with meaningful EV-to-Revenue only.

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-12-13), Rani Therapeutics Holdings's stock price is $1.66. Rani Therapeutics Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $0.00. Therefore, Rani Therapeutics Holdings's PS Ratio for today is .


Rani Therapeutics Holdings EV-to-Revenue Historical Data

The historical data trend for Rani Therapeutics Holdings's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rani Therapeutics Holdings EV-to-Revenue Chart

Rani Therapeutics Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
- - 102.68 - -

Rani Therapeutics Holdings Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Rani Therapeutics Holdings's EV-to-Revenue

For the Biotechnology subindustry, Rani Therapeutics Holdings's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rani Therapeutics Holdings's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rani Therapeutics Holdings's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Rani Therapeutics Holdings's EV-to-Revenue falls into.



Rani Therapeutics Holdings EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Rani Therapeutics Holdings's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=61.290/0
=

Rani Therapeutics Holdings's current Enterprise Value is $61.29 Mil.
Rani Therapeutics Holdings's Revenue for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Rani Therapeutics Holdings  (NAS:RANI) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Rani Therapeutics Holdings's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=1.66/0
=

Rani Therapeutics Holdings's share price for today is $1.66.
Rani Therapeutics Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Rani Therapeutics Holdings EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Rani Therapeutics Holdings's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Rani Therapeutics Holdings Business Description

Traded in Other Exchanges
N/A
Address
2051 Ringwood Avenue, San Jose, CA, USA, 95131
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads up to 200 microlitre in liquid form with high bioavailability.
Executives
South Cone Investments Limited Partnership 10 percent owner AVENIDA PRESIDENTE RIESCO 5711 OFICINA 1, LAS CONDES, SANTIAGO F3 7550000
Talat Imran director, officer: CEO C/O RANI THERAPEUTICS HOLDINGS, INC., 2051 RINGWOOD AVENUE, SAN JOSE CA 95131
Quiroga Cortes Isidoro Alfonso 10 percent owner 9020 N CAPITAL OF TEXAS HWY, SUITE I-260, AUSTIN TX 78759
Jean Luc Butel director ONE BAXTER PARKWAY, DEERFIELD IL 60015
Maulik Nanavaty director BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752-1234
Kate Mckinley officer: CHIEF BUSINESS OFFICER C/O RANI THERAPEUTICS HOLDINGS, INC., 2051 RINGWOOD AVE., SAN JOSE CA 95131
Svai S Sanford officer: CFO C/O RANI THERAPEUTICS LLC, 2051 RINGWOOD AVE., SAN JOSE CA 95131
Eric Groen officer: General Counsel C/O RANI THERAPEUTICS HOLDINGS, INC., 2051 RINGWOOD AVE., SAN JOSE CA 95131
Mir Hashim officer: Chief Scientific Officer C/O RANI THERAPEUTICS HOLDINGS, INC., 2051 RINGWOOD AVENUE, SAN JOSE CA 95131
South Lake One Llc 10 percent owner 250 WEST 55TH STREET, NEW YORK NY 10019
Aequanimitas Limited Partnership 10 percent owner LEONEL AGUIRRE 1830, UNIT 101, MONTEVIDEO X3 11500
Mir A Imran director
Andrew Farquharson director C/O RANI THERAPEUTICS HOLDINGS, INC., 2051 RINGWOOD AVENUE, SAN JOSE CA 95131
Laureen Debuono director
Lisa Ann Rometty director C/O RANI THERAPEUTICS HOLDINGS, INC., 2051 RINGWOOD AVE., SAN JOSE CA 95131